A randomized pilot study of cyclosporin G in renal transplantation

  • S. Ohlman
  • H. Gäbel
  • H. Wilczek
  • G. Tydén
  • C. -G. Groth
  • A. Lindholm
  • J. Säwe
  • F. Reinholt
Conference paper


Animal studies have suggested that the analogue cyclosporin G (CyG) may be less nephrotoxic than cyclosporin A (CyA). A pilot study was therefore performed in 10 primary cadaveric renal allograft recipients who were randomized to receive posttransplant immunosuppression with either CyA or CyG. The follow-up time was a minimum of 1 year. One graft was lost in each group. All patients in both groups experienced at least one acute rejection episode. Episodes of acute nephrotoxicity were observed in both groups. Renal function, as assessed by determinations of the serum creatinine level and chromium-ethylene diamine tetra-acetic acid (Cr-EDTA) clearance, did not differ between the two groups. Renal allograft biopsies showed a significantly higher degree of fibrosis in the CyG group than in the CyA group. All CyG-treated patients evidenced laboratory signs of acute liver toxicity, which was dose-dependent and reversible. Today, all CyG-treated patients have been switched to CyA. This study shows that immunosuppression after renal transplantation in man is possible with CyG; however, it does not seem to have any advantages over CyA.

Key words

Immunosuppression Cyclosporin A Cyclosporin G Renal transplantation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. l.
    Beveridge T, Gugerli U, Huser B, Thiel G (1987) OG 37–325 tolerability/efficacy and first pilot studies in organ transplantation. Sandoz, BaselGoogle Scholar
  2. 2.
    Calne RY (1987) Cyclosporine in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet 2:506–507PubMedCrossRefGoogle Scholar
  3. 3.
    Calne RY, Wood A J (1985) Cyclosporin in cadaveric renal transplantation: 3-year follow-up of a European multicentre trial. Lancet 2:549PubMedCrossRefGoogle Scholar
  4. 4.
    Calne RY, White DJG, Thiru S (1978) Cyclosporivne A in patients receiving renal allografts from cadaver donors. Lancet II: 1323–1327CrossRefGoogle Scholar
  5. 5.
    Calne RY, White DJG, Thiru S, Rolles K, Drakopoulos S, Jamieson NV (1985) Cyclosporin G: immunosuppressive effect in dogs with renal allografts. Lancet 1:1342PubMedCrossRefGoogle Scholar
  6. 6.
    Canadian Multicenter Transplant Study Group (1983) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809–815CrossRefGoogle Scholar
  7. 7.
    Collier St J, Calne RY, White DJG, Winters S, Thiru S (1986) Blood levels and nephrotoxicity of cyclosporin A and G in rats. Lancet 1:216PubMedCrossRefGoogle Scholar
  8. 8.
    Donatsch P, Ruffel D (1986) Effects of cyclosporine A and G on renal function. Experientia 42:668Google Scholar
  9. 9.
    Duncan JI, Whiting PH, Simpson JG, Thomson A (1985) Nephrotoxicity of cyclosporin G in rats. Lancet II: 1004–1005CrossRefGoogle Scholar
  10. 10.
    Duncan JI, Thomson AW, Simpson JG, Davidson RJL, Whiting PH (1986) A comparative toxicological study of cyclosporine and Nva2-cyclosporine in Sprague-Dawley rats. Transplantation 42:395–399PubMedCrossRefGoogle Scholar
  11. 11.
    European Multicentre Trial Group (1983) Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet II: 986–989CrossRefGoogle Scholar
  12. 12.
    Faraci M, Vigeant C, Yale JF (1988) Pharmacokinetic profile of cyclosporine A and G and their effects on cellular immunity and glucose tolerance in male and female Wistar rats. Transplantation 45:617–621PubMedCrossRefGoogle Scholar
  13. 13.
    Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, Loertscher R, Lemaire M, Nussbaumer K, Niederberger W, Wood A (1983) Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34:638–643PubMedCrossRefGoogle Scholar
  14. 14.
    Grant D, Zhong R, Stiller C, Wallace C, Keown P, Duff J (1987) A comparison of cyclosporin A and Nva2-cyclosporine (cyclosporine G) in a rat allograft model. Transplantation 44:9–12PubMedCrossRefGoogle Scholar
  15. 15.
    Grant D, Freeman P, Keown P, Stiller C, Toman A, Blacker K (1987) Pharmacokinetic and pharmacodynamic profiles of cyclosporine and cyclosporine G in dogs. Transplant Proc 19: 3494–3495PubMedGoogle Scholar
  16. 16.
    Grant Hoyt E, Billingham ME, Maseh MA, Morris RE, Baldwin JC, Jamieson SW (1985) Assessment of cyclosporine G, a new immunosuppressant agent. Heart Transplant 4: 616Google Scholar
  17. 17.
    Hagberg RC, Hoyt EG, Billingham ME, Sibley RK, Starnes VA, Baldwin JC (1988) Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive efficacy, toxicity and pharmacokinetics in Lewis rats. J Heart Transplant 7:359–369PubMedGoogle Scholar
  18. 18.
    Hiestand PC, Gunn HC, Gale JM, Ryffel B, Borel JF (1985) Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2)dihydrocyclosporine. Immunology 55:249–255PubMedGoogle Scholar
  19. 19.
    Hiestand PC, Gunn H, Gale J, Siegl H, Ryffel B, Donatsch P, Borel JF (1985) The immunosuppressive profile of a new natural cyclosporine analogue: Nva2-cyclosporine. Transplant Proc 17: 1362–1364Google Scholar
  20. 20.
    Huser B, Landmann J, Mihatsch M, Bianchi L, Thiel G (1987) Clinical pilot study with cyclosporine G in kidney transplant recipients. Kidney Int 32:431CrossRefGoogle Scholar
  21. 21.
    Lundgren G, Groth C-G, Albrechtsen D, Brynger H, Flatmark A, Frödin L, Gäbel H, Husberg B, Klintmalm G, Maurer W, Persson H, Thorsby E (1986) HLA-matching and pretransplant blood transplantations in cadaveric renal transplantation — a changing picture with cyclosporine. Lancet II: 66–69CrossRefGoogle Scholar
  22. 22.
    Lundgren G, Albrechtsen D, Brynger H, Flatmark A, Frödin I, Gäbel H, Persson H, Groth CG (1987) Improved early course after cadaveric renal transplantation by reducing the cyclosporine dose and adding azathioprine. Transplant Proc 19: 2074–2079PubMedGoogle Scholar
  23. 23.
    Masri MA, Naiem M, Pingle S, Daar AS (1988) Cyclosporine A versus cyclosporine G: a comparative study of survival, hepato-toxicity, nephrotoxicity and splenic atrophy in BALB/c mice. Transplant Int 1:13–18CrossRefGoogle Scholar
  24. 24.
    Myers BD (1986) Cyclosporine nephrotoxicity. Kidney Int 30: 964–974PubMedCrossRefGoogle Scholar
  25. 25.
    Myers BD, Ross J, Newton, Luetscher J, Perlroth M (1984) Cy-closporine-associated chronic nephropathy. N Engl J Med 311: 699–705PubMedCrossRefGoogle Scholar
  26. 26.
    Ogunnaike HO, Starkey TD, Baldwin JC, Porter KA, Billingham ME, Jamieson SW (1987) An assessment of Nva2-cyclosporine in primate cardiac transplantation. Transplantation 43: 13–17PubMedCrossRefGoogle Scholar
  27. 27.
    Porter GA, Bennett WM (1986) Chronic cyclosporine-associated nephrotoxicity. Transplant Proc 18:204–209PubMedGoogle Scholar
  28. 28.
    Prop J, Hoyt EG, Jamieson SW (1987) (Nva2)-cyclosporine — less potent than cyclosporin A in rats with lung and heart transplants. Transplantation 44:5–8PubMedCrossRefGoogle Scholar
  29. 29.
    Shibata N, Minoucki T, Hayashi Y, Ono T, Shimakawa H (1987) Qualitative determination of cyclosporin A in whole blood and plasma by high performance liquid chromatography. Res Commun Chem Path Pharmacol 57:261–271Google Scholar
  30. 30.
    Sommerauer JF, Grant D, Freeman D, Mineault R, Duff J, Wall W (1989) Effect of cholestasis on cyclosporine metabolism in the pig. Transplant Proc 21:835–836PubMedGoogle Scholar
  31. 31.
    Stiller CR (1984) Update for the Canadian multicenter trial of cyclosporine in renal allografts. N Engl J Med 310:1464–1465PubMedGoogle Scholar
  32. 32.
    Tejani A, Lancman I, Pomrantz A, Khawar M, Chen C (1988) Nephrotoxicity of cyclosporine A and cyclosporine G in a rat model. Transplantation 45:184–187PubMedCrossRefGoogle Scholar
  33. 33.
    Thiru S, Mahler ER, Hamilton DV, Evans DB, Calne RY (1983) Tubular changes in renal transplant recipients on cyclosporine. Transplant Proc 15 [Suppl 1]: 2846–2851Google Scholar
  34. 34.
    Todo S, Porter KA, Kam I, Lynch S, Venkataramanan R, DeWolf A, Starzl TE (1986) Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation 41:296–300PubMedCrossRefGoogle Scholar
  35. 35.
    Traber R, Loosli HR, Hoffmann H, Kuhn M, Von Wartburg A (1982) Isolierung und Strukturermittlung der neuen cyclosporine E, F, G, H and I. Helv Chir Acta 65:1655–1677CrossRefGoogle Scholar
  36. 36.
    Venkataramanan R, Todo S, Zaghloul I, Lynch S, Kam I, Ptachinski RJ, Burckart GJ, Starzl TE (1987) Comparative pharmacokinetics of cyclosporine and Nva2-cyclosporine in dogs. Transplant Proc 19:1265–1266PubMedGoogle Scholar
  37. 37.
    Wenk M, Bindschedler M, Costa E, Zuber M, Vozeh S, Thiel G, Abisch E, Keller HP, Beveridge T, Follath F (1988) Pharmacokinetics of cyclosporine G in patients with renal failure. Transplantation 45:558–561PubMedCrossRefGoogle Scholar
  38. 38.
    Wilczek H (1989) Renal allograft biopsy. Core and fine needle biopsy techniques for acute diagnosis and long-term follow-up. Academic thesis, Huddinge Hospital, Karolinska Institute, study III, pp 12–14Google Scholar
  39. 39.
    Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R (1990) Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 22:1305–1311PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • S. Ohlman
    • 1
  • H. Gäbel
    • 1
  • H. Wilczek
    • 1
  • G. Tydén
    • 1
  • C. -G. Groth
    • 1
  • A. Lindholm
    • 1
    • 2
  • J. Säwe
    • 2
  • F. Reinholt
    • 3
  1. 1.Departments of Transplantation SurgeryHuddinge Hospital, Karolinska InstituteStockholmSweden
  2. 2.Departments of Clinical PharmacologyHuddinge Hospital, Karolinska InstituteStockholmSweden
  3. 3.Departments of PathologyHuddinge Hospital, Karolinska InstituteStockholmSweden

Personalised recommendations